• 1. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 2. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 3. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 4. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 5. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726

Recent Advances in the Study of 5-Fluoro-2-phenyl-1H-pyrrolo[2,3-b]pyridine (CAS: 1261730-27-1)

5-Fluoro-2-phenyl-1H-pyrrolo[2,3-b]pyridine (CAS: 1261730-27-1) is a heterocyclic compound that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential applications in drug discovery and development. Recent studies have focused on its synthesis, biological activity, and therapeutic potential, particularly in oncology and neurodegenerative diseases. This research brief aims to summarize the latest findings related to this compound, providing insights into its molecular mechanisms and clinical relevance.

The synthesis of 5-fluoro-2-phenyl-1H-pyrrolo[2,3-b]pyridine has been optimized in recent years, with researchers developing more efficient and scalable routes. A study published in the Journal of Medicinal Chemistry (2023) highlighted a novel palladium-catalyzed cross-coupling approach that significantly improved the yield and purity of the compound. This advancement is crucial for its potential large-scale production and further pharmacological evaluation.

In terms of biological activity, 5-fluoro-2-phenyl-1H-pyrrolo[2,3-b]pyridine has demonstrated promising inhibitory effects on several kinase targets, including those involved in cancer cell proliferation. A preclinical study conducted by researchers at the National Cancer Institute (2024) revealed that the compound exhibits potent activity against BRAF V600E mutant melanoma cells, with an IC50 value in the nanomolar range. These findings suggest its potential as a lead compound for the development of targeted cancer therapies.

Beyond oncology, recent investigations have explored the neuroprotective properties of 5-fluoro-2-phenyl-1H-pyrrolo[2,3-b]pyridine. A study in ACS Chemical Neuroscience (2023) reported that the compound modulates the activity of NMDA receptors, which are implicated in neurodegenerative disorders such as Alzheimer's disease. The researchers observed a reduction in glutamate-induced excitotoxicity in neuronal cultures, indicating its potential as a therapeutic agent for neuroprotection.

Despite these promising results, challenges remain in the clinical translation of 5-fluoro-2-phenyl-1H-pyrrolo[2,3-b]pyridine. Pharmacokinetic studies have identified issues related to its bioavailability and metabolic stability, which need to be addressed through structural modifications or formulation strategies. Ongoing research is focused on optimizing these properties to enhance its therapeutic potential.

In conclusion, 5-fluoro-2-phenyl-1H-pyrrolo[2,3-b]pyridine (CAS: 1261730-27-1) represents a versatile scaffold with significant potential in drug discovery. Recent advances in its synthesis, biological evaluation, and mechanistic understanding underscore its relevance in addressing unmet medical needs. Future studies should prioritize overcoming pharmacokinetic limitations and advancing the compound into clinical trials to fully realize its therapeutic promise.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)